iShares Global 100
What Do Analysts Expect from PepsiCo’s 2Q16 Earnings?
PepsiCo’s (PEP) performance in recent quarters has been under pressure due to currency headwinds and weakness in carbonated soft drink volumes.
Why Philip Morris’s 1Q16 Market Share Declined in Asia
Net revenue for Philip Morris’s (PM) Asia region decreased 8.7% to ~$2 billion in 1Q16. This compares to $2.2 billion in 1Q15.
Overview: 3 things to know about currency hedging
Your total return depends on both equity and currency returns, which are sensitive to economic, political, and market events, and fluctuate over time.
Merck’s 4Q17 Estimates: Pharmaceutical Segment
Merck & Co.’s (MRK) diabetes portfolio is expected to report a decline in operating revenues in 4Q17 due to lower sales of Janumet.
Johnson & Johnson’s Growth Rate for 4Q17
Johnson & Johnson (JNJ) reported 11.5% growth in its revenues to ~$20.2 billion during 4Q17, compared to ~$18.1 billion during 4Q16.
Analyst Ratings and Recommendations for Johnson & Johnson
JNJ stock has risen 27.9% in the last 12 months. Analysts estimate that the stock could rise 1.4% over the next 12 months.
Behind Pfizer’s Business Segments in 1Q17
Pfizer’s Innovative Health segment contributes ~58% of PFE’s total revenues and reported an operational growth of 6% to $7.4 billion for 1Q17.
How AstraZeneca’s Oncology Segment Performed in 1Q17
AstraZeneca’s (AZN) Oncology segment has consistently reported revenue growth over the last few years, and it’s one of the company’s key areas of focus.
Why Novartis’s 1Q17 Revenues Missed Analysts’ Estimates
Novartis (NVS) released its 1Q17 earnings on April 25, 2017, reporting a 25.0% rise in revenues at constant exchange rates compared to 1Q16.
What Analysts Predict for AstraZeneca’s 1Q17 Earnings
Analysts estimate AstraZeneca will post EPS (or earnings per share) of $0.40 and revenues of $5.4 billion in 1Q17.
How Does Pfizer’s Valuation Compare to Peers?
Pfizer (PFE) reported an 8% increase in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015.
AstraZeneca’s Other Products Segment Is Losing Market Share
For 2016, Synagis reported 2% growth at constant exchange rates, following its 14% growth in sales in the US.
Chart in Focus: Performance of AstraZeneca’s Growth Platforms in 2016
AstraZeneca’s (AZN) Respiratory Product sales fell 3% at constant exchange rates to ~$4.8 billion during fiscal 2016.
Coca-Cola Keeps Its Focus on Still Beverages for Future Growth
Coca-Cola’s (KO) still beverage volumes have seen higher growth compared to sparkling or soda beverages.
Coca-Cola’s 2Q16 Revenue Fell Due to Headwinds
Coca-Cola generated revenue of $11.5 billion in fiscal 2Q16 ending July 1, 2016. It missed analysts’ consensus revenue estimate of $11.6 billion.
Can Walmart Deliver Operating Margin Expansion amid Headwinds?
In fiscal 1Q17, Walmart’s operating margin declined by about 40 basis points to 4.6% mainly due to a rise in expenses associated with the planned wage rate increase in the Walmart US and Sam’s Club segments.
P&G’s Stock Price Reaction to the Old Spice Lawsuit
After a lawsuit was filed against Procter & Gamble (PG), or P&G, for its Old Spice deodorant, P&G’s stock price opened with a fall of 0.4% to $82.46 on March 24, 2016.